A team of Chinese researchers has uncovered a promising new avenue for treating Alzheimer’s disease, publishing their findings in the journal *Cell*. The scientists identified the cholecystokinin B receptor (CCKBR) – a protein abundant in the brain’s memory hub, the entorhinal cortex – as a critical player in learning and memory. In mouse models, loss of CCKBR caused severe memory deficits, suggesting that boosting its activity could protect cognition. Building on this insight, the team designed a small‑molecule drug called 3r1 that binds specifically to CCKBR and, crucially, can cross the blood‑brain barrier. In laboratory experiments, 3r1 reduced neuronal and synaptic damage, cleared toxic amyloid‑beta plaques, and restored signaling pathways that normally deteriorate as Alzheimer’s progresses. The researchers also observed that severe dementia patients have weakened CCKBR‑Gq signaling, while an opposing Gi pathway becomes overactive, highlighting the receptor’s role in disease stages. If these results translate to humans, 3r1 could become the first therapy that directly targets CCKBR to slow or even reverse Alzheimer’s decline. The discovery offers fresh hope for millions worldwide and marks a significant step toward a disease‑modifying treatment for this devastating neurodegenerative disorder.
Read more